Particle.news
Download on the App Store
8 ARTICLES
·
yesterday

Lilly and Nvidia Unveil Pharma-Scale AI Factory Built on DGX SuperPOD

Lilly expects the system to start running in January, with commercial payoffs from AI-enabled discovery likely closer to 2030.

HANOVER, GERMANY - MARCH 31: The Nvidia logo flashes at a stand at the 2025 Hannover Messe industrial trade fair on March 31, 2025 in Hanover, Germany. The fair, which showcases German and international industrial production, is taking place as trade relations between the European Union and the United States are becoming fractured by the threat of tariffs by the administration of U.S. President Donald Trump. (Photo by Sean Gallup/Getty Images)
The Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake/File Photo
A smartphone with a displayed NVIDIA logo is placed on a computer motherboard in this illustration taken March 6, 2023. REUTERS/Dado Ruvic/Illustration
Image

Overview

  • Eli Lilly will own and operate an Nvidia DGX SuperPOD using DGX B300 systems to power a dedicated AI factory for drug discovery and development.
  • The buildout is slated to finish in December, with the supercomputer going online in January according to company timelines.
  • The system will use more than 1,000 Blackwell Ultra GPUs to train large biomedical foundation models on millions of experiments to broaden and speed early research.
  • Select proprietary models will be shared through Lilly TuneLab using federated learning, allowing biotechs to benefit from Lilly-trained models without directly exchanging sensitive data.
  • Lilly and Nvidia highlight applications spanning imaging, digital twins for biomanufacturing, and AI agents for R&D workflows, while noting no AI-designed drugs are yet on the market.